Stock REGN REGENERON PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Real-time Estimate Cboe BZX
Other stock markets
 03:24:22 2024-05-24 pm EDT 		5-day change 1st Jan Change
986.3 USD +0.59% Intraday chart for Regeneron Pharmaceuticals, Inc. +0.35% +12.23%
May. 23 Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer MT
May. 23 Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regeneron Pharmaceuticals Says GN7075 Plus Libtayo Shows Anti-Tumor Responses in Microsatellite Stable Colorectal Cancer
Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075
ETF de la semana: Los “utilities” desempeñan un papel en la aparición del AII
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,855,489, According to a Recent SEC Filing
Regeneron, Sanofi Disclose Positive Results for Lung Disease Treatment Candidate
Compañías que se deben tener muy en cuenta por técnico este lunes en Wall Street
Regeneron Pharmaceuticals Insider Sold Shares Worth $22,355,714, According to a Recent SEC Filing
Regeneron Pharmaceuticals Insider Sold Shares Worth $48,636,545, According to a Recent SEC Filing
Sector Update: Health Care Stocks Mixed Late Afternoon
ETF de la semana: India y Brasil podrían despertar
Regeneron Pharmaceuticals Insider Sold Shares Worth $35,207,110, According to a Recent SEC Filing
MIDDAY BRIEFING - Unternehmen und Märkte -2-
FDA prüft Antrag von Regeneron und Sanofi für Dupixent vorrangig
Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Dupixent Supplemental Application for Priority Review
Sanofi : la FDA accorde un examen prioritaire à Dupixent dans la rhinosinusite
Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Dupixent
Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
Sector Update: Health Care Stocks Mixed Premarket Thursday
Regeneron : BPA ajusté en repli de 4% au 1er trimestre
Fed, Earnings Outlooks Lift Wall Street Pre-Bell; Asia Mixed, Europe Off
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. REGN Stock
  4. News Regeneron Pharmaceuticals, Inc.
  5. Other languages